$SOLV

Solventum Corp

Solventum develops, manufactures and commercializes healthcare products and services for hospitals, physicians, clinics and other healthcare providers around the world. Its products and services support patient care from prevention and diagnosis through treatment and recovery. Solventum is headquartered in Eagan, Minnesota. Solventum has three business segments. MedSurg offers wound care, skin care, surgical supplies, infection prevention products and medical technologies. Dental Solutions sells dental and orthodontic products, including brackets, aligners, restorative cements and bonding agents. Health Information Systems provides healthcare software for clinical documentation, coding, revenue cycle processes and data visualization. The company makes money by selling products and software through direct sales, distributors, key account management, inside sales and e-commerce, with local partners supporting sales in emerging geographies. It sells in over 90 countries.

5
1
0

No SEC Form 4 filings for $SOLV in the last 30 days.

See all $SOLV insider activity →

SOLV Energy Q3 2026 slides: record revenue, raised guidance

SOLV Energy reported Q3 2026 revenue of $1.24B, up 65% YoY, and raised full-year guidance. Net income rose 75% to $123M, but margins compressed. The company's backlog reached $9.2B, and it acquired ASB Energy Services for $45M. Shares fell 1.02% to $27.30 despite strong results.

SOLV sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning SOLV (Solventum Corp). Coverage has skewed bullish: 5 bullish, 1 neutral, and 0 bearish.

Recent SOLV coverage spans earnings, financial news and market movers.

What's driving SOLV

AlphAI scores every news story that mentions SOLV with an AI model for sentiment and relevance, and aggregates insider trades from Solventum Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SOLV

Score

SOLV Energy Q3 Revenue Rises 65% to $1.24 Billion; Raises 2026 Guidance

SOLV Energy reported Q3 2026 revenue of $1.24B, up 65% YoY, with net income of $123M. Adjusted EBITDA was $173M, and gross margin was 17.8%. The company raised its 2026 guidance for revenue, adjusted gross profit, and adjusted EBITDA. Growth was driven by new construction and existing infrastructure revenue. SOLV completed its acquisition of ASB Energy Services in October 2026.

Top Medical Supply Stock Picks From BTIG

BTIG raised its price target for Solventum Holdings (SOLV) to $100 after strong Q3 results. SOLV reported $1.949B revenue and $1.45 EPS, beating estimates. The company raised guidance for organic growth, operating margins, and EPS. BTIG cited operational execution and cost management as key factors.

Solventum Q3 Earnings Call Highlights

Solventum reported Q3 sales of $1.9B, with mixed performance across segments. Gross margin rose to 57.1%, while operating margin fell to 19.9%. The company raised its full-year earnings outlook to $7.20-$7.30 per share and expects high-end organic sales growth. It also announced plans to separate its Health Information Systems business and renegotiated a raw material supply agreement with 3M.

$SOLVHighAI 8/10Earnings

Solventum Reports Third Quarter 2026 Financial Results

Solventum (NYSE: SOLV) reported Q3 2026 sales of $1.9B, down 7.0% YoY, with organic sales down 2.8%. Adjusted EPS was $1.45, down 3.6%. The company expects full-year organic sales growth toward the high end of +2.5% to +3.0% and raised adjusted EPS guidance to $7.20-$7.30. Operating cash flow was $177M, and free cash flow was $97M. The company completed ERP system cutovers and exited ~90% of 3M transition service agreements.

Related tickers